ML Strategies Health Care Preview - May 2019 #2

Mintz - Health Care Viewpoints
Contact

This week, the full House is poised to take its first action on drug pricing, voting on a pair of bills that would improve access to drug patents. The first bill is H.R. 1520, the Purple Book Continuity Act of 2019, which would codify the publication of patents of approved biological products in the Purple Book, which is a list of approved or licensed biological products. The second bill is H.R. 1503, the Orange Book Transparency Act of 2019, would ensure that relevant patent information in the Orange Book is updated timely and accurately. The Orange Book is a list of approved drug products and therapeutic equivalents. The House is also expected to vote on the Protecting Americans with Preexisting Conditions Act.

Please see full publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Mintz - Health Care Viewpoints

Written by:

Mintz - Health Care Viewpoints
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Mintz - Health Care Viewpoints on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide